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CANADA UPDATE: SUPREME COURT
SUPPORTS THE PMPRB's ABILITY TO




I. INTRODUCTIONIN January, the Supreme Court of Canada bolstered the government's
ability to regulate the prices charged for patented medicines used by
Canadians.1 In Celgene Corp. v. Attorney General of Canada, the
court unanimously affirmed the Federal Court of Appeals decision and
held that the Patented Medicine Price Review Board (PMPRB) has the
ability to control the prices of Canadian patented medicines sold in for-
eign countries to Canadian consumers. 2 Relying primarily upon the legis-
lative intent of the Patent Act in creating the PMPRB, the court
approved the Board's interpretation of its authority over drugs sold by
Celgene in the United States subsequently shipped to Canadian patients. 3
In doing so, the court pronounced that the clear purpose of the enabling
legislation would control the interpretation of what it understood to be a
textual ambiguity regarding the Board's jurisdiction.4 The court also indi-
cated that it would apply a deferential standard of review when a tribunal
is interpreting its enabling legislation.5
II. BACKGROUND
This case stemmed from the refusal of Celgene, a global pharmaceuti-
cal company, to submit sales records of its brand-name drug Thalomid as
requested by the PMPRB. 6 Celgene, formed in 1980 as a spinoff from the
merger of the Celenese and Hoechest corporations, obtained approval
from the U.S. Food and Drug Administration in 1998 to promote
* Candidate for Juris Doctor, SMU Dedman School of Law 2011.
1. See generally Celgene Corp. v. Att'y Gen. of Can., 2011 SCC 1 (Can.).
2. Id. 91 32, 35.
3. Id. f% 1, 26.
4. See id. 1 25, 32, 35.
5. Id. 1 33.
6. Celgene Corp. v. Attorney Gen. of Can., [2009] F.C.R. 271, 1 10, 11 (Can.).
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Thalomid as a treatment for leprosy and related illnesses.7 Later, in 2006,
Celgene obtained approval for Thalomid's use in the treatment of multi-
ple myeloma, a form of cancer.8 But Canada has generally banned the
use of thalidomide, the primary active ingredient in Thalomid, since the
early 1960s, when it was identified as causing birth defects in the children
born to women taking the drug to combat nausea and sleep loss during
pregnancy.9 Until recently, Thalomid was only available to Canadians
through the Special Access Program (SAP).' 0
Under the SAP, physicians are able to obtain drugs that are not ap-
proved for general use in Canada on behalf of specific patients "with seri-
ous or life-threatening conditions on a compassionate or emergency basis
when conventional therapies have failed, are unsuitable, or are unavaila-
ble."" The Therapeutics Product Directorate in Health Canada reviews
each application under the SAP, and allows the physician to prescribe
and order the drug once it determines that the "need is legitimate" and
that the physician is qualified.12 In its analysis, the Directorate will con-
sider each application for the drug on an individual basis using factors
such as urgency and condition of the patient.' 3 Even with approval, the
SAP Program limits the amount of drug available per approval to a six-
month supply and requires the sponsoring physicians to monitor and re-
port adverse reactions to Health Canada.14
7. History of Celgene Corporation, CELGENj, http://www.celgene.com/about-celgene/
biopharmaceutical-company-about.aspx (last visited Feb. 17, 2011).
8. See Thalomid Authorization For Sale in Canada, HEAL In CANADA, http://
www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/thalidomide
fs_fd-eng.pdf (last visited Feb. 17, 2011).
9. Id.
10. See id.
11. Special Access Programme-Drugs, HEALITH CANADA, http://www.hc-sc.gc.ca/dhp-
mps/alt-formats/hpfb-dgpsa/pdf/acces/sapfspasfd_2002-eng.pdf (last visited Feb.
17, 2011). In the typical process for drug development and approval, a pharmaceu-
tical company obtains a Canadian patent for the new drug and conducts preclinical
testing on tissue cultures and small animals. Drugs from Research Lab to Phar-
macy Shelf, CANADIAN PHARMACISTS Ass'N, http://www.pharmacists.ca/content/
hcp/resource-centre/drug-therapeuticinfopdf/DrugApprovalProcess.pdf (last
visited Feb. 17, 2011). Once the drug is found to be promising, a formal applica-
tion is made to Health Canada to start a clinical trial. Id. With approval, the
company conducts several phases of clinical trials culminating in a review process
by the Therapeutic Products Directorate within the Health Products and Food
Branch. Id. With successful completion of the review process and upon authoriza-
tion of the "new drug and its manufacturing process," Health Canada provides a
Notice of Compliance (NOC) and a Drug Identification Number allowing the
company to manufacture, market, and sell the drug within Canada. Id.
12. How Drugs Are Reviewed in Canada, HE-ALIIm CANADA, http://www.hc-sc.gc.cal
dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/reviewfs-examenfd-eng.pdf (last
visited Feb. 17, 2011).
13. Janet N. Chong, The Canadian Special Access Program, DeE-Tii WILLIAMS WALL,
http://www.dww.com/dww/wp-content/uploads/2007/06/SpecialAccess-Chong.pdf
(last visited Mar. 29, 2011).
14. Special Access Programme-Drugs, supra note 11. Since this case was originally
brought, Thalomid has been made available through a new program called
RevAid. Thalomid Authorization For Sale in Canada, supra note 8. In the
RevAid "controlled distribution program," specially registered physicians are able
to register patients. Id. This program essentially forgoes the individualized ap-
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Celgene has made Thalomid available under the SAP since 1995.'5 But
until 2006, Celgene had not been issued a Canadian patent for its brand
name drug.16 Celgene's Canadian patents in this case involve methods
for the formation of thalidomide and its use in combination with other
drugs for the treatment in a variety of health problems.' 7 Once Celgene
was granted its first patent, 2,166,315, in April of 2006, the PMPRB con-
tacted the company and requested pricing information regarding
Thalomid.' 8 This request was based upon section 80 of the Patent Act
which allows the Board to obtain "information and docu-
ments ... [regarding] the price at which medicine is being or has been sold
in any market in Canada and elsewhere."19 As a result, although
Thalomid was already being sold under the SAP unregulated by the
PMPRB, once Celgene obtained a patent and restricted others' use of
thalidomide in the Canadian market, the PMPRB sought information to
appropriately regulate the price paid by Canadians for the drug.20
In response to the PMPRB, Celgene provided pricing information for
the period after it received its patent, April 5, 2006; however, the Board
requested pricing information for all times after Celgene had made
Thalomid available to the Canadian market after the publication of its
patent application-January 12, 1995.21 Celgene refused to provide this
information and brought a jurisdictional challenge to the board's ability
to regulate the pricing of Thalomid, arguing that the Board could not
regulate the price charged because the drug was sold under the SAP pro-
gram rather than "general commercial marketing" and because commer-
proval required through the SAP while allowing Health Canada to obtain and re-
tain data concerning benefits and risks. See id.
15. Geoffrey North & Catherine Newnham, Supreme Court of Canada Finds Patented
Medicine Prices Review Board Has Jurisdiction Over Price of Thalomid in Canada,




16. See Muller, George W., "Process for the Preparation of Thalidomide," Can. Patent
No. 2,166,315 filed Jul 1, 1994, and issued April 4, 2006; see also, D'Amato, Robert
J., "Methods and Compositions for Inhibition of Angiogenesis," Can. Patent No.
2,270,887 filed Nov. 4, 1997 and issued March 21, 2006; see also, D'Amato, Robert,
"Methods and Compositions for Inhibition of Angiogenesis," Can. Patent No.
2,157,288 field Feb. 24, 1994 and issued Nov. 8, 2005. At roughly the same time,
the U.S. Food and Drug Administration approved the use of "thalidomide in com-
bination with dexamethasone for the treatment of multiple myeloma." Thalomid
Authorization For Sale in Canada, supra note 8.
17. See generally Can. Patent Nos. 2,166,315, 2,270,887, and 2,157,288, supra note 16.
18. Celgene Corp., [2009] F.C.R. 271, $ 10.
19. Patent Act, R.S.C. 1985, c. P-4, § 80(1)(b) (Can.).
20. See Thalomid Authorization For Sale in Canada, supra note 8; see also William A.
W. Neilson, Robert G. Howell & Souichirou Kozuka, Intellectual Property Rights
and Competition Law and Policy: Attempts in Canada and Japan to Achieve A
Reconciliation, 1 WASII. U. GLooAL Smun. L. REv. 323, 338 (2002); Celgene Corp.,
[2009] F.C.R. 271, 1 10.
21. Can. Patent No. 2,166,315, supra note 16; see also Celgene Corp, [2009] F.C.R. 271,
1 10; Steven Mason, The PMPRB's Jurisdiction-Back to the Date of Publication,
MCCARTmY TETRAULr, Dec. 20, 2007, http://www.mccarthy.calarticle-detail.aspx?
id=3809.
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cial law defined the sale as occurring in the United States.22 The
PMPRB's judicial arm rejected this challenge, and Celgene brought the
matter before the Federal Court pursuing the argument that, per com-
mercial law, the sale should be designated as occurring extra-territorially
such that the Board lacked authority over the sale because the payment
was made in U.S. dollars, in New Jersey, and the product was shipped
free on board.23 Upon judicial review, the court accepted this argument
and held that the Board lacked jurisdiction under § 80(1)(b) of the Patent
Act to regulate prices when the sales occur outside of Canada. 24 The
Attorney General of Canada, representing the Board, appealed, and the
Federal Court of Appeals reversed, relying primarily upon the legislative
purpose of the PMPRB, and found that the Board could regulate prices
of Canadian Patented medicines to Canadian consumers when sold from
abroad into the Canadian market. 25
III. REGULATION OF CANADIAN MEDICINE PRICE AND
THE PMPRB
Canadian health care is administered provincially through its Medicare
plan, providing universal health care under "criteria set forth in the 1984
Canadian Health Care Act." 26 Since the system is publicly financed, the
government has a strong incentive to regulate the price charged for
pharmaceuticals. 27 In order to limit exorbitant pricing, Canada originally
used compulsory licensing whereby generic drug manufacturers could
forcibly take a license-a government enforced limitations of the right of
exclusivity of the patent owner. 28 The generic manufacturer would then
be able to produce a drug and market it, typically for a lower price than
the patent holder would charge.29 Because compulsory licensing tended
to act as a disincentive to drug development, the government sought to
catalyze innovation by allowing patent holders a right to completely ex-
clude for a limited period of time and amended the Patent Act.30 But to
control prices, in the amendment, the government also established the
Patented Medicines Price Review Board with the ability to regulate
prices based on a market median price in seven western industrialized
22. Celgene Corp., [2009] F.C.R. 271, 9 11.
23. Id. 99 9-11. Per free on board, delivery occurs when a seller relinquishes goods at
a port for shipment, in this case, the United States. See FOB Free on Board, INT'l
CIIAM3ER OF COMM., (2000), http://www.iccwbo.org/incoterms/preambles/pdfl
FOB.pdf.
24. Celgene Corp., [2009] F.C.R. 271, 1 37.
25. Att'y Gen. of Can. v. Celgene, [20091 F.C.A. 378, 315 DL.R. 4th 270, T9 55-59
(Can. C.A.).
26. Jennifer L. Halser, Canadian Pharmacies: A Prescription For a Public Health Dis-
aster, 54 DEPAuL L. RF:v 543, 549 (2005).
27. Michael B. Moore, "Open Wide" (Your Pocketbook That Is)-A Call for the Estab-
lishment in the United States of a Prescription Drug Price Regulatory Agency, 1 Sw.
J. L. & TRADE AM. 149, 162 (1994).
28. Id.
29. Id.
30. Id. at 163.
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nations.31 For excessive prices, the PMPRB is able to "order the patentee
to reduce the price and take measures to offset any excess revenues it
may have received." 32
In order to determine whether a price is excessive, the PMPRB typi-
cally relies upon sales information that the company provides.33 Without
direct information from the drug companies, the PMPRB could not effec-
tively evaluate the prices charged for medicines; they would have to rely
upon "highly subjective statistical data produced by the drug companies,"
to determine whether "the drug companies [were obtaining] a fair return
on their investment." 34 In addition to the sales data provided, the
PMPRB also takes into account other factors such as comparing prices of
drugs already on the Canadian market with similar therapeutic benefits
and the amount invested by drug companies in development.35 The
PMPRB indicates that in 2009, of the 1,003 patented drugs sold in Ca-
nada, 91.5% were sold at prices within the prescribed PMPRB guide-
lines.36 The PMPRB's analysis also indicates that the prices spent by
Canadians on these patented medicines is roughly twenty percent higher
than that of the lowest of the seven comparative industrialized nations
but seventy-one percent lower than the highest of the seven nations.37
Thus, the steps taken by the PMPRB have been effective in ensuring that
Canadians have access to medicines at a reasonable price in a system that
encourages new drug development. 38
IV. THE SUPREME COURT OF CANADA PRIORITIZES
CONSUMER PROTECTION
In finding on behalf of the PMPRB, the Supreme Court of Canada held
that the overarching purpose for the implementation of the Board con-
trolled over a commercial law contractual understanding regarding the
sale of an item. 39 The primary argument that Celgene proposed was that
because the sale occurred in the United States, the Board lacked jurisdic-
tion over the price charged for Thalomid.40 Celgene argued that its sale
of Thalomid in a foreign country, albeit to Canadian citizens, does not
implicate the Board's powers to regulate the price because the jurisdic-
31. Jenifer A. Orange, Canada and U.S. Approaches to Cross-Border Sales of
Pharmaceuticals, 31 CAN.-U.S. L. J. 317, 318 (2005). These nations include United
Kingdom, France, Germany, Italy, Switzerland, Sweden, and the United States. Id.
32. Patented Medicine Price Review Board, Annual Report 2009, TREASURY BD. OF
CAN. SECRETARIAT, http://www.pmprb-cepmb.gc.ca/cmfiles/ar09-en-online.pdf
(last visited Mar. 8, 2011).
33. See Moore, supra note 27, at 163.
34. Id.
35. Davina Rosen, Balancing Business & National Health: The Impact of Legislation
on Pharmaceutical Drug Prices, 26 TEMP. J. Sci. TEcH. & ENVrt. L. 341, 355
(2007).
36. Patented Medicine Price Review Board, Annual Report 2009, supra note 32, at 10.
37. Id. at 29, T. 11.
38. Id.
39. Celgene Corp., 2011 SCC 1, T1 24, 25.
40. See id. 1 6.
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tion of the Board is limited to sales in Canada.41
But in conferring authority to the Board, the Patent Act states that a
"patentee of an invention pertaining to a medicine shall . . . provide the
Board with such information and documents . . . respecting . . . the price
at which the medicine is being sold . . . in any market in Canada and
elsewhere." 42 Moreover, Patent Act § 83(1) states that the Board's reme-
dial power applies to "a patentee of an invention pertaining to a medicine
[thati is selling the medicine in any market in Canada." 43 Celgene argued
that because the words of the statute are clear and unambiguous, they
should have priority over any interpretation of the "overriding purpose of
the statute."44
For example, in Canada Trustco Mortgage Co. v. R., the Supreme
Court of Canada had relied upon a textual reading of the relevant statute
and the common interpretation of the term "cost" as the "price that the
taxpayer gave up in order to get the asset" and would not stray to rede-
fine "cost" as "money at risk." 45 Celgene argued that, in the same way,
the court should rely on the common interpretation of a "sale" as under-
stood in the commercial context. 46 Celgene attempted to strengthen its
position by providing evidence of the commercial meaning of the term
"sale," so that "sale in any market in Canada" per § 83(1) of the Patent
Act limits the PMPRB's regulatory authority to a commercial sale occur-
ring in Canada. 47 To define "sale," Celgene relied upon Deputy Minister
of National Revenue v. Mattel Canada, Inc. where the court analyzed in
detail the vending process by a foreign entity for "export to Canada
under s[ection] 48(4) of the Customs Act." 48 But the court found that
while Mattel does discuss "sale," it considered it from an import duty
context, which was not relevant to the understanding of "sale" in the con-
text of the PMPRB's jurisdiction. 49
The court, however, did not find the issue of the commercial meaning
of "sale" to be determinative.50 The court also considered "sale" as it
relates to patents.5 In Domco Industries Ltd. v. Mannington Mills Inc.
the plaintiff's claim of infringement failed because an alleged infringer
41. See id.
42. Patent Act, § 80(1).
43. Id. § 83(1).
44. See Celgene Corp., 2011 SCC 1, 21.
45. Can. Trustco Mortg. Co. v. R., [2005] 2 S.C.R. 601, % 69-71 (Can.). The court's
accepted definition was supported by the respondent's interpretation of the pur-
pose of the Income Tax Act.
46. Celgene Corp., 2011 SCC 1, 1 21.
47. Id. 11 22-23.
48. Deputy Minister of Nat'l Revenue v. Mattel Can. Inc., [2001 2 S.C.R. 100, 1 8
(Can.).
49. Celgene Corp., 2011 SCC 1, % 23; see Mattel Can. Inc., [2001] 2 S.C.R. 100, 1$ 34-
53.
50. See Celgene Corp., 2011 SCC 1, 1 24, 25.
51. See id.; Mattel Can. Inc., [2001] 2 S.C.R. 100, 1 35.
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did not sell the patented item within Canada.52 In Domco, the court
stated that when delivery occurs outside of Canada and where the con-
tract for sale of infringing goods are not proven to be within Canada,
there is no vending of the goods locally to infringe the patent per the
Patent Act § 46.53 This result is supported by the commonly accepted
view that patent laws are territorial.54 Despite the fact that commercial
laws and patent laws could define "sale" as having occurred abroad, the
court felt the purpose of the statute-protecting Canadians from exces-
sive drug prices-allowed the PMPRB to regulate drugs which relied on
Canadian patents and avail the Canadian market.55 Moreover, the court
considered that accepting a purely commercial law interpretation of
"sale" as controlling would result in the PMPRB having authority over
Canadian pharmaceuticals sold in Canada for export. 56 Because the ju-
risdiction of the PMPRB should not extend to foreign consumers, the
court felt justified in avoiding an outcome based purely on the commer-
cial and patent law interpretation of "sale." 57
The court concluded that the PMPRB was authorized to seek
Celgene's sales records to 1995 for two reasons.58 First the court gave
deference to the PMPRB and used a reasonableness standard of review.59
In this regard, the court followed it prior holding from New Brunswick v.
Dunsmiur where it stated that "[d]eference will usually result where a
tribunal is interpreting its own statute or statutes closely connected to its
function." 60 In this case, the PMPRB was interpreting its jurisdiction
under the Patent Act, which created the Board, and thus the court would
only set aside the Board's decision if it were to fall outside a range of
possible, acceptable outcomes which are defensible in respect of the facts
and law." 61
Second, because the court felt that the textual authority was unpersua-
sive, it turned to the purpose of the PMPRB for guidance and found con-
sumer protection to be mandated by the legislative history. 62 The
PMPRB was formed with the amendment of the Patent Act, which, at the
same time, limited the availability of compulsory licensing. 63 The court
noted that in introducing the Bill C-22 that created the PMPRB, the Hon.
Harvie Andre stated that "[t]hese changes will also ensure consumer pro-
tection by creating a drug prices review board to monitor drug prices."64
52. Mattel Can. Inc., [2001] 2 S.C.R. 100, $ 35; see Domco Indus. Ltd. v. Mannington
Mills Inc., [1990] 107 N.R. 198, 35 (Can.).
53. Domco Indus., 107 N.R. 198, $ 35; Patent Act, § 46.
54. See Neilson, Howell & Kozuka, supra note 20, at 337.
55. Celgene Corp., 2011 SCC 1, $ 32.
56. See id. $ 11.
57. Id.
58. See id. 1 33, 34.
59. Id. % 34.
60. Dunsmuir v. N.B. Bd. of Mgmt., [2008] 1 S.C.R. 131, $ 54 (Can.).
61. Celgene Corp., 2011 SCC 1, 34; Dunsmuir, [2008] 1 S.C.R. 131, 1 47.
62. Celgene Corp., 2011 SCC 1, % 28.
63. Halser, supra note 26, at 553.
64. Celgene Corp., 2011 SCC 1, % 26.
2011] 393
394 LAW AND BUSINESS REVIEW OF THE AMERICAS [Vol. 17
Moreover, with the later amendment of the Patent Act in 1993, the Hon.
Pierre Blaise, "reiterated the Board's consumer protection mandate."65
As a result of the legislative history and with prior holdings, the court
found support for the consumer protection mandate and the holding of
the PMPRB.66
V. CONCLUSION
In summary, the Supreme Court of Canada has supported the
PMPRB's mandate in protecting Canadian consumers from excessive
drug prices. The court determined that the PMPRB was justified in ask-
ing Celgene to provide the prices it charged for Thalomid even when sold
extraterritorially and shipped under the SAP policy. For Celgene, the
outcome may be of little practical concern as Thalomid has been recently
approved for sale through the RevAid process, and the original volumes
in the SAP process, though a significant percentage of total SAP sales,
were inconsequential in terms of absolute numbers. 67 This case demon-
strates the court's approval of regulation by the PMPRB and its increas-
ing broadening of the PMPRB's jurisdiction.68 As such, Celgene v.
Attorney General of Canada is a case that drug manufacturers that pursue
the Canadian marketplace should consider. 69
65. Id. 1 27.
66. See id. $$ 26-30.
67. Thalomid Authorization For Sale in Canada, supra note 8 (noting that in 2009 the
SAP received 6300 requests for Thalomid and that Celgene earned $108 Million in
total Thalomid sales for 2009); Celgene Reports Record Fourth Quarter and Full
Year 2009 Product Sales and Operating Income, Fm-RcE3 Bionmcii, Jan. 28, 2010,
http://www.fiercebiotech.com/press-releases/celgene-reports-record-fourth-quar-
ter-and-full-year-2009-product-sales-and-operating-.
68. Mason, supra note 21.
69. Borden Ladner Gervais, Barbara Mclsaac & Kristen Crain, Supreme Court of Ca-
nada Confirms Patented Medicine Prices Review Board Interpretation of the Term
"Sold in Any Market in Canada" and Underlines the Consumer Protection Pur-
poses of the Board's Role, Ass'N. oF CORP. COUNSEL, Jan. 21, 2011, http://
www.lexology.com/library/detail.aspx?g=3ed289f0-ca43-4f41-bcO3-91ce43c27dd6.
